WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Intercept Pharmaceuticals
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
FUJIFILM Diosynth Biotechnologies | July 28, 2020
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...
Medical
BioVaxys | June 09, 2022
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity ass...
Cell and Gene Therapy, Industrial Impact
bioAffinity Technologies, Inc. | December 19, 2022
bioAffinity Technologies, Inc. a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff. Jennifer Rebeles, Ph.D., has been promoted to Vice President of Diagnostics. Dr. Rebeles joined bioAffinity in 2019 as Director of Diagnostics where she led the team of scientists in the research and development of t...
Industrial Impact
OMass Therapeutics | February 21, 2022
OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE